GLP1R and dementia: Importantly, treatment with GLP-1 RAs was shown to have a reduced hazard ratio for dementia in both RCT data (HR = 0.47, 95% CI: 0.25–0.86) and real-world evidence from a nationwide Danish cohort (HR = 0.89, 95% CI: 0.86–0.93), thereby supporting their potential for disease modification beyond metabolic control [130].